Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Am J Hematol. 2021 Jun 1;96(6):735-746. doi: 10.1002/ajh.26142. Epub 2021 Mar 18.

Abstract

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Adrenal Cortex Hormones / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Arsenic Trioxide / adverse effects
  • Arsenic Trioxide / pharmacology
  • Arsenic Trioxide / therapeutic use
  • Cell Differentiation / drug effects
  • Clinical Trials as Topic
  • Cytokine Release Syndrome / chemically induced*
  • Cytokine Release Syndrome / diagnosis
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / mortality
  • Edema / chemically induced
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Epigenesis, Genetic / drug effects
  • Fever / chemically induced
  • Humans
  • Hypotension / chemically induced
  • Isocitrate Dehydrogenase / antagonists & inhibitors
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy*
  • Molecular Targeted Therapy / adverse effects
  • Myelopoiesis / drug effects*
  • Neoplasm Proteins / antagonists & inhibitors
  • Pleural Effusion / chemically induced
  • Respiration Disorders / chemically induced
  • Tretinoin / adverse effects
  • Tretinoin / pharmacology
  • Tretinoin / therapeutic use
  • fms-Like Tyrosine Kinase 3 / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Tretinoin
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Arsenic Trioxide